chemical factory

Tesamorelin Peptide CAS 218949-48-5 | China Manufacturer & Supplier

From my lab to your bench, I offer Tesamorelin ,Tesamorelin Peptide ,CAS 218949-48-5, Tesamorelin Research Peptide ,Tesamorelin Lyophilized Powder, Tesamorelin Supplier ,Tesamorelin Manufacturer. Based in China, I’m a dependable China Manufacturer focused on high-purity peptides for research use. My Tesamorelin lyophilized powder is produced under stringent controls, delivering stable shelf life, precise dosage, and reproducible results across batches. Each lot is characterized for identity and purity with a certified CAS 218949-48-5 match, and I provide COA and packaging details with every shipment. Researchers value steady supply and clear documentation, so I keep lead times short and pricing transparent. I’m open to collaborations with biopharma labs, contract research sites, and academic groups seeking a reliable Tesamorelin Supplier. As a dedicated Tesamorelin Manufacturer, I can adjust quantities, packaging, and documentation to fit your project scale. Reach out today to discuss your order, delivery options, and long-term partnership opportunities.

Hot Selling Product

Tesamorelin ,Tesamorelin Peptide ,CAS 218949-48-5, Tesamorelin Research Peptide ,Tesamorelin Lyophilized Powder, Tesamorelin Supplier ,Tesamorelin Manufacturer Supplier Trusted by Pros

Tesamorelin (CAS 218949-48-5) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) used in endocrine and metabolic research. In lyophilized powder form it offers enhanced stability and extended shelf life, ideal for laboratories requiring consistent supply. Purity is typically high (often ≥ 98% by HPLC), with clear reconstitution guidelines to preserve activity during investigations. It is intended for laboratory use only. For global buyers, sourcing Tesamorelin means prioritizing GMP-compliant manufacturing, rigorous QA, and transparent documentation such as COAs, MSDS, and lot traceability. A reliable supplier provides consistent batch-to-batch potency, scalable quantities, and flexible packaging of lyophilized vials for various project scopes. Logistics support includes temperature-controlled shipping and worldwide distribution to help meet timelines while maintaining product integrity. Ensure clear terms on storage, handling, and regulatory compliance to support responsible research collaboration.

{ Tesamorelin ,Tesamorelin Peptide ,CAS 218949-48-5, Tesamorelin Research Peptide ,Tesamorelin Lyophilized Powder, Tesamorelin Supplier ,Tesamorelin Manufacturer Supplier Trusted by Pros}

Attribute Details
Name Tesamorelin (Growth Hormone-Releasing Hormone analogue)
CAS Number 218949-48-5
Type / Category Peptide; GHRH analogue
Amino acid length 44 amino acids
Mechanism of action Stimulates release of growth hormone from the anterior pituitary by activating the GHRH receptor
Indications / Approved use Used for HIV-associated lipodystrophy (FDA-approved indication in 2010)
Formulation Lyophilized powder (for reconstitution)
Route of administration Subcutaneous injection
Storage Store lyophilized powder at -20°C; reconstituted solution should be stored refrigerated and used as directed
Regulatory/status Approved for clinical use in specific lipodystrophy indications; widely used in research contexts as a GHRH analogue

Related Products

Logistics and Transportation

Tesamorelin ,Tesamorelin Peptide ,CAS 218949-48-5, Tesamorelin Research Peptide ,Tesamorelin Lyophilized Powder, Tesamorelin Supplier ,Tesamorelin Manufacturer in 2025 Factory-Direct Excellence

Dose-Response and Time-Dependent Efficacy for a Growth Factor Peptide (Arbitrary Units)

Explanation: This chart presents the dose-response and time-dependent efficacy of a peptide growth factor under three dosing regimens over a 12-week period. The x-axis denotes weeks since treatment initiation, from 0 to 12. The y-axis shows an efficacy index on a 0–100 scale, representing a composite biomarker response or functional outcome in this illustrative dataset. Each line corresponds to a different dose: 0.5 mg, 1.0 mg, and 2.0 mg. The data were generated to illustrate generic pharmacodynamic patterns rather than to reflect any clinical result. In week 0, all regimens start near baseline, indicating an initial stabilization after administration. By week 4, the 2.0 mg dose demonstrates a more pronounced rise, reaching around 60 in the index, followed by continued improvement through week 12 to approximately 90. The 1.0 mg dose follows a similar, albeit steeper trajectory than the lowest dose, peaking in the mid-80s by week 12. The 0.5 mg dose shows more modest gains, approaching the low-70s by the end of the observation period. The divergence between regimens illustrates a clear dose-dependent pharmacodynamic effect, with higher doses yielding larger and faster responses but with signs of ceiling effects as the index saturates near the top of the scale. The chart also highlights the role of time as a driver of efficacy beyond mere dosage; even the lowest dose exhibits a gradual, accumulative improvement, suggesting cumulative exposure or delayed downstream signaling. This visualization aids hypothesis generation and supports planning for more formal analyses, such as mixed-effects modeling, to quantify dose-response relationships, inter-individual variability, and time-to-peak effects. The legend clarifies which color corresponds to which dose, while the axes and gridlines help interpret magnitude and timing. It is important to note that these values are synthetic and intended for demonstration; real pharmacology studies would incorporate confidence intervals, replication, and statistical validation. Future work could include confidence intervals, bootstrap analyses, cross-validation with independent datasets, and consideration of pharmacokinetic data such as half-life and accumulation.

Top Selling Products